Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

Who May Qualify: - Biopsy proved treatment-naïve AL amyloidosis - Fluorescence in situ hybridization (FISH) t(11;14) ≥ 10% - dFLC \> 50mg/L Who Should NOT Join This Trial: - Co-morbidity of uncontrolled infection - Co-morbidity of other active malignancy - Co-diagnosis of multiple myeloma or waldenstrom macroglobulinemia - Co-morbidity of grade 2 Mobitz II or grade 3 atrioventricular block (expect for those with implanted pacemaker) - Co-morbidity of sustained or recurrent nonsustained ventricular tachycardia - Seropositive for human weakened immune system virus - Hepatitis B virus (HBV)-DNA \> 1000 copies/mL - Seropositive for hepatitis C (except in the setting of a sustained virologic response) - Systemic treatment with moderate or strong cytochrome P450 3A （CYP3A） inducers, moderate or strong CYP3A inhibitors within 7 days prior to the first dose of study drug - Neutrophil \<1×10E9/L，hemoglobin \< 8g/dL，or platelet \< 100×10E9/L - Severely compromised hepatic or renal function: alanine transaminase (ALT) or aspertate aminotransferase (AST) \> 2.5 × upper limit of normal (ULN), total bilirubin \> 3 × ULN，eGFR \< 15 mL/min, or receiving renal replacement therapy Always talk to your doctor about whether this trial is right for you.